Veritas In Silico’s CEO, Shingo Nakamura, and senior investigator, Ella Morishita, recently published an article in Expert Opinion on Drug Discovery, where they delve into unleashing the full potential of RNA-targeted small molecule drug discovery through artificial intelligence (AI).

Traditional drug discovery has focused on targeting disease-related proteins with small molecules. Recent research efforts, including those spearheaded by Veritas In Silico, have paved the way for a paradigm shift from the traditional protein-targeted to RNA-targeted drug discovery. These efforts led to the accumulation of vast amounts of data on disease-related RNAs, as well as on small molecules that target RNAs. This article reviews how AI is being used to analyze the large datasets, find useful information within them, and assist decision-making during the various stages of drug discovery. Furthermore, the article provides perspectives on future research directions to further leverage AI and enhance the efficiency, precision, and success rates in RNA-targeted drug discovery.

Read the full publication here:
Full article: Recent applications of artificial intelligence in RNA-targeted small molecule drug discovery (tandfonline.com)